Meeting
2015 ASCO Annual Meeting
CD137 co-stimulation and blocking PD-1 enhances NK cell-mediated target cell lysis by CD30/CD16A TandAb AFM13.
Authors
Xing Zhao
Tissue Engineering and Stem Cells Research Center, Department of Immunology, Guiyang Medical University, Guiyang, China
Xing Zhao , Narendiran Rajasekaran , Uwe Reusch , Jens-Peter Marschner , Martin Treder , Holbrook Edwin Kohrt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immunotherapy and Biologic Therapy
Citation
J Clin Oncol 33, 2015 (suppl; abstr 3050)
DOI
10.1200/jco.2015.33.15_suppl.3050
Abstract #
3050
Poster Bd #
376
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Efficacy and immune modulation by BXCL701 a dipeptidyl peptidase inhibitor, NKTR-214 a CD122-biased immune agonist with PD1 blockade in murine pancreatic tumors.
First Author: Luca Rastelli
Poster
2023 ASCO Annual Meeting
Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated biliary tract cancer.
First Author: Wen-Zhuo He
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II study of paclitaxel and carboplatin plus PD-1 inhibitors combined with anlotinib as first-line treatment for advanced esophageal cancer.
First Author: Mingfang Xu
Poster
2020 ASCO Virtual Scientific Program
Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): Secondary and final primary efficacy analyses.
First Author: Daniel V.T. Catenacci